Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) EBITDA (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed EBITDA for 4 consecutive years, with -$3.1 million as the latest value for Q4 2024.

  • Quarterly EBITDA rose 37.57% to -$3.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$13.9 million through Dec 2024, up 12.89% year-over-year, with the annual reading at -$20.4 million for FY2025, 46.75% down from the prior year.
  • EBITDA hit -$3.1 million in Q4 2024 for Pasithea Therapeutics, down from -$3.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $623344.0 in Q4 2021 to a low of -$5.0 million in Q4 2023.
  • Historically, EBITDA has averaged -$2.9 million across 4 years, with a median of -$3.3 million in 2023.
  • Biggest five-year swings in EBITDA: plummeted 897.6% in 2022 and later soared 37.57% in 2024.
  • Year by year, EBITDA stood at $623344.0 in 2021, then tumbled by 897.6% to -$5.0 million in 2022, then fell by 1.47% to -$5.0 million in 2023, then skyrocketed by 37.57% to -$3.1 million in 2024.
  • Business Quant data shows EBITDA for KTTA at -$3.1 million in Q4 2024, -$3.0 million in Q3 2024, and -$3.9 million in Q2 2024.